Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by VectorY Therapeutics

News headline image
VectorY Expands PIONEER-ALS Phase 1/2 Clinical Trial Size
From VectorY Therapeutics
Via Business Wire
News headline image
VectorY Therapeutics Receives U.K. MHRA Authorization and EMA Approval to Initiate Phase 1/2 PIONEER-ALS Clinical Trial of VTx-002 in People Living with Amyotrophic Lateral Sclerosis (ALS)
From VectorY Therapeutics
Via Business Wire
News headline image
VectorY Therapeutics Announces First Participant Dosed in Phase 1/2 PIONEER-ALS Clinical Trial of VTx-002 in People with Amyotrophic Lateral Sclerosis (ALS)
From VectorY Therapeutics
Via Business Wire
News headline image
VectorY Therapeutics Appoints Kevin Pojasek, Ph.D., to Board of Directors
From VectorY Therapeutics
Via Business Wire
News headline image
VectorY Therapeutics Receives FDA Fast Track Designation for VTx-002, a First-in-Class Vectorized Antibody Targeting Underlying Disease Biology in ALS
From VectorY Therapeutics
Via Business Wire
News headline image
VectorY Therapeutics Receives FDA Clearance of IND to Proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002, a First-in-Class Vectorized Antibody Targeting TDP-43 Pathology in ALS
From VectorY Therapeutics
Via Business Wire
News headline image
VectorY Therapeutics and Shape Therapeutics Announce Option and License Agreement to Advance Vectorized Antibodies for Neurodegenerative Diseases Using an AAV5-Derived CNS Capsid
From VectorY Therapeutics
Via Business Wire
News headline image
VectorY Therapeutics Appoints Jessica Atkinson as Chief Business Officer
From VectorY Therapeutics
Via Business Wire
News headline image
VectorY Therapeutics to Present Preclinical Data on Novel ALS Therapeutic Strategy at Target ALS Conference in Boston
From VectorY Therapeutics
Via Business Wire
News headline image
VectorY Therapeutics Announces Multiple Presentations at Upcoming American Society of Gene and Cell Therapy Annual Meeting 2025
From VectorY Therapeutics
Via Business Wire
News headline image
VectorY Therapeutics Appoints Olga Uspenskaya-Cadoz as Chief Medical Officer
From VectorY Therapeutics
Via Business Wire
News headline image
VectorY Strengthens Leadership Team with Appointment of Jim Scibetta as New CEO
From VectorY Therapeutics
Via Business Wire
News headline image
VectorY Appoints Seasoned Biotech Leader Adam Rosenberg as Chair of the Board
From VectorY Therapeutics
Via Business Wire
News headline image
VectorY Appoints Khurem Farooq to Board of Directors
From VectorY Therapeutics
Via Business Wire
News headline image
VectorY Announces Participation in Scientific Conferences in October 2022
From VectorY Therapeutics
Via Business Wire
News headline image
VectorY to Present Two Posters at the American Society of Gene and Cell Therapy’s (ASGCT) 25th Annual Meeting
From VectorY Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback